Introduction
von Willebrand factor (VWF) is a multimeric, adhesive plasma protein that facilitates the attachment of platelets at the site of vascular injury, and also binds coagulation factor VIII in plasma to protect it from proteolysis [1] . Defective function or decreased levels of VWF results in von Willebrand disease (VWD). Type 3 VWD is categorized by a virtually complete deficiency of VWF, whereas type 1 VWD encompasses partial quantitative VWF deficiency [1] . The reduced survival of VWF in plasma is one mechanism causing type 1 VWD, often referred to as type 1C (clearance) VWD [2] [3] [4] [5] [6] . In these patients VWF undergoes essentially normal synthesis, secretion and multimerization, but the secreted VWF is quickly cleared from plasma [2] [3] [4] [5] . The type 1C VWD phenotype can be identified by assay of VWF antigen (VWF:Ag) and VWF propeptide (VWFpp) [4, 5, 7, 8] . VWF and VWFpp are secreted into plasma on an equimolar basis and circulate independently of one another with disparate half-lives of 8-14 h and 2-3 h, respectively [9, 10] . The molar concentration of plasma VWFpp is less than that of VWF, although each is defined as 1.0 U mL À1 . Consequently, in normal human plasma the VWFpp/VWF:Ag ratio is 1.0. Type 1C VWD subjects exhibit decreased plasma levels of VWF due to rapid VWF clearance from plasma, but have a normal VWFpp half-life, resulting in an increased VWFpp/VWF: Ag ratio [4, 5] . In addition, after DDAVP administration in humans, the plasma concentration of VWF and VWFpp increases due to release from endothelial cell Weibel-Palade bodies, but the VWFpp/VWF is elevated (range of 4-10), reflecting regulated release on an equimolar, but not 'equiunit', basis [5, 11] . A reduced VWF survival phenotype has also been identified in the RIIIS/J mouse strain [12] . These mice demonstrated low VWF:Ag levels and normal multimer distribution. The reduced VWF levels in this mouse were found to be caused by a defect outside of the VWF gene [13] . Further studies identified the Mvwf1 mutation that leads to altered lineage-specific expression of an N-acetylgalactosaminyltransferase gene, B4galnt2 (previously Galgt2) [14] . The Mvwf1 allele switches B4galnt2 gene expression from intestinal epithelial cell specific to vascular endothelial cells, thus affecting the post-translational modification of VWF. This glycan-modified VWF was shown to have reduced survival in plasma, similar to the type 1C phenotype described in VWD patients. Interestingly, given the importance of glycan structures in regulating human VWF structure and function, Johnsen and colleagues recently demonstrated that the Mvwf1 allele is actually present in a number of different strains of mice, including some wild-derived strains [15] .
In this study, we sought to further characterize the significance of Mvwf1 expression in relation to VWF biology. In addition, we have investigated the utility of the murine VWFpp/VWF:Ag ratio in identifying mice with reduced VWF survival.
Materials and methods

Antibodies
Anti-murine VWFpp antibodies 349.2 and 349.3 and antimurine VWF antibody 344.3 were produced by the Hybridoma Core Laboratory at the BloodCenter of Wisconsin. Briefly, recombinant murine VWFpp or propeptide-deleted murine VWF (mature VWF only) proteins were expressed in HEK293T cells. Mice were immunized and hybridomas generated. A rabbit polyclonal antihuman VWF that cross-reacts with murine VWF was purchased from DAKO (Carpinteria, CA, USA).
Animals and procedures
C57BL/6J, A/J, CAST/EiJ, RIIIS/J, PERA/EiJ and VWF-/-mouse strains were purchased from Jackson Laboratories. Tie2-B4galnt2 mice backcrossed >20 generations to C57BL/6J were obtained from the laboratory of David Ginsburg (University of Michigan, Ann Arbor) [14] . Mice were bred and housed at the Medical College of Wisconsin. All mouse procedures and experiments were performed according to protocols approved by the Medical College of Wisconsin's Institutional Animal Care and Use Committee.
Blood collection methods
Retro-orbital. Mice were anesthetized using isoflurane or ketamine/xylazine. Blood was removed from the retroorbital plexus using either a single or multiple successive heparin-coated capillary tube(s).
Submandibular.
A mouse bleeding lancet (Medipoint, Mineola, NY, USA) was used to puncture the large vein draining the head and the cheek skin area that passes down the jaw at the back end of the cheek pouch. After the lancet was used to puncture the vein, blood was removed from the submandibular vein using a heparincoated capillary tube.
Cardiac puncture. Mice were anesthetized with ketamine/xylazine. Some mice were treated with heparin. The anesthetized mouse was laid on its back and a syringe with a 25-gauge needle was pushed vertically through the sternum. The needle was inserted 5 mm from the center of the thorax towards the animal's chin, holding the syringe 25-30 degrees away from the chest. When blood appeared in the syringe, the plunger was gently pulled back to obtain the maximum amount of blood available.
Vena cava. Mice were either treated with heparin or injected with 200 lL of 3.2% (w/v) sodium citrate into the vena cava prior to blood collection. The mice were anesthetized with ketamine/xylazine and the abdominal cavities were opened widely below the rib cage. The intestines were retracted to the left and the liver was pushed forward. A 25 or 26-gauge needle on a 1-mL syringe was carefully inserted into the aorta or vena cava and blood drawn slowly until the vessel collapsed; this was repeated as necessary until sufficient blood had been collected.
Tail tip (tail vein). The mice were placed into a small animal restraint, the tail disinfected with 70% isopropyl alcohol and 3 mm of the tail clipped using a sharp, sterile scalpel blade. The clipped tail was suspended in 80 lL of 3.2% sodium citrate solution and gently massaged until 20 lL of blood was collected. Once the blood was collected, the tail was removed from the citrate and the bleeding was controlled by the application of direct pressure to the wound and cauterized if necessary.
Saphenous vein. The rear limb of a mouse immobilized in a conical restrainer was shaved and disinfected. Gentle pressure was applied above the knee and the saphenous vein was punctured with a 23-gauge 1/2" needle. The resulting blood flow was collected in a heparin-coated capillary tube. Direct pressure was applied to the puncture site until bleeding stopped.
Endothelial-VWF, platelet-VWF and liver-VWF mice
Mice expressing VWF only in endothelial cells (EC-VWF) or platelets (Plt-VWF) were generated by reciprocal bone marrow transplantation between C57BL/6J (wild-type) and VWF-deficient (VWF-/-) mice as previously described [16] . Recipients were analyzed, beginning at 8 weeks after bone marrow transplantation. Mice expressing VWF only in liver (liver-VWF) were generated by hydrodynamic tail vein injection of a plasmid expressing murine VWF sequence (kind gift of David Ginsburg, University of Michigan, Ann Arbor) with a CMV promotor [17, 18] . Briefly, murine-VWF cDNA diluted in saline (1.5-3.5 mL, approximately 10% bodyweight) was injected rapidly (5-15 s) into the tail vein of a VWF-/-mouse at a constant rate, inducing transient expression of murine VWF with blood samples collected approximately 24 h after hydrodynamic injection [19] .
VWF clearance studies
Murine plasma containing VWF protein was delivered intravenously by tail vein injection into VWF-/-mice. Blood was collected by retro-orbital bleed immediately after injection and at five additional time-points over the next 2-24 h. Fluids were replaced by subcutaneous injection of 1.0 mL of 0.9% sterile saline at the time that the second blood sample was obtained. Data were analyzed using GraphPad Prism v5.00 (GraphPad Software, San Diego, CA, USA). The half-life was calculated using a two-phase model of exponential decay: Y = A*exp (-k fast *t) + B*(exp(-k slow *t) and t 1/2 = ln 2/k [20] .
VWF and VWFpp assays
Murine VWF:Ag level was determined by antigen capture ELISA using a monoclonal anti-murine VWF antibody 344.3 as capture antibody and biotinylated polyclonal anti-VWF (Dako Carpinteria, CA, USA) for detection of captured murine VWF. Murine VWFpp level was determined by antigen capture ELISA using monoclonal antiVWFpp antibody 349.3 as capture antibody and biotinylated monoclonal anti-VWFpp antibody 349.2 for detection of captured VWFpp [17] . A pool of C57BL/6J plasma (collected by cardiac puncture using citrate in the syringe) was used as calibrator and assigned a value of 1.0 U mL À1 . For determination of VWF:Ag and VWFpp level in murine platelets, platelets were isolated from murine whole blood as previously described [16] . Platelets were counted and platelet pellets frozen at À80°C. Platelet pellets were suspended in ice cold lysis buffer (0.5% 3-((3-cholamidopropyl) dimethylammonio)-1-propanesulfonate) by vigorous vortexing, incubated on ice for 10 min, and then microfuged for 10 min at 4°C. Platelet lysates were used immediately for VWF:Ag and VWFpp ELISA. Murine plasma VWF multimer structure was assessed by 2% SDS-agarose electrophoresis and western blotting with polyclonal anti-VWF antibody (DAKO, Glostop, Denmark) as previously described [21] .
Results
Optimization of murine blood collection techniques
In preliminary studies, we observed differences in murine plasma VWF levels that appeared to vary according to phlebotomy technique. To determine the most reliable method for blood sampling in mice such that endothelial and platelet VWF secretion are minimized, several blood platelets (plt-VWF) or only in endothelial cells (EC-VWF) were generated (Fig. 1A) . Plt-VWF and EC-VWF mice were subjected to vena cava blood collection (Fig. 1B) or multiple successive retro-orbital bleeds (Fig. 1C) , and plasma VWF:Ag and VWFpp determined. In EC-mice, VWF and VWFpp levels after vena cava collection averaged 0.5 U mL À1 with a VWFpp/VWF:Ag of 1.06. Plt-VWF mice demonstrated no detectable level of either VWF or VWFpp after vena cava collection, which is consistent with VWF sequestration in the platelet and indicates undetectable levels of sample activation. In contrast, after multiple successive retro-orbital bleeds, plasma VWF and VWFpp levels were increased in EC-VWF mice, with an approximately 4-fold increase in VWFpp and 1.7-fold increase in VWF compared with vena cava collection method. The elevated VWFpp/VWF:Ag of 3.01 suggests endothelial activation. In Plt-VWF mice, plasma VWFpp and VWF levels were considerably increased after multiple successive retro-orbital bleeds, with a markedly elevated VWFpp/VWF:Ag of 25.8 indicating platelet activation. Both endothelial cell and platelet activation contribute to procedure-related release of VWF and VWFpp.
Evaluation of plasma and platelet VWF in mice with and without Mvwf1 variant allele
Decreased survival of VWF in mice is known to commonly result from the murine genetic variant, Mvwf1 [14, 15, 22] . We surveyed strains of mice with Mvwf1 (RIIIS/J, PERA/ EiJ), a transgenic model of Mvwf1 (Tie2-B4galnt2), and strains without Mvwf1, which exhibit low/normal VWF levels (C57BL/6J, A/J) and high VWF levels (CAST/EiJ) [15, 18] . Blood was obtained and plasma VWF:Ag and VWFpp determined (Table 2) . VWF levels were reduced in RIIIS/J, PERA/EiJ and Tie2-B4galnt2 mice with Mvwf1 compared to A/J and C57BL/6J mice. In contrast, VWF levels were markedly elevated in CAST/EiJ mice. VWFpp levels were similar between these strains, although Tie2-B4galnt2 mice had slightly reduced VWFpp. VWFpp/ VWF:Ag was elevated in RIIIS/J, PERA/EiJ and Tie2-B4galnt2 mice with Mvwf1 compared to A/J and C57BL/6J mice, whereas CAST/EiJ mice demonstrated a reduced VWFpp/VWF:Ag. VWF:Ag and VWFpp levels in platelets were also determined using platelet lysates (Table 3) . VWF level was increased in CAST/EiJ mice compared with C57BL/6J and A/J mice, whereas Mvwf1-positive mice were similar to A/J and C57BL\6J mice. VWFpp was increased in CAST/EiJ mice compared with C57BL/6J mice and A/J mice, whereas VWFpp levels in Mvwf1 mice were roughly similar to those in A/J and C57BL\6J mice. The ratio of VWFpp/VWF:Ag was fairly consistent between all strains of mice, ranging from 1.3 to 2.3. Some strains of mice, including C57BL/6J, produce a truncated form of ADAMTS-13 with reduced activity, whereas other strains such as CASA/Rk and 129x1/Sv mice produce fulllength protein, which may affect VWF multimer structure; thus we examined VWF multimer structure in mice [23] . All strains of mice demonstrated a normal full spectrum of multimers, with CAST/EiJ mice demonstrating a subtle loss of the very highest molecular weight multimers. PERA/EiJ and CAST/EiJ strains showed evidence of VWF satellite bands, indicating cleavage by ADAMTS-13 ( Fig. 2) .
Clearance of VWF in a VWF-/-model
We examined the clearance of plasma VWF obtained from mice with and without Mvwf1 after injection into the VWF-/-mouse (Fig. 3) . Plasma VWF from RIIIS/J and Tie2-B4galnt2 mice with Mvwf1 was cleared from plasma quickly with undetectable levels by 3 hours after injection, consistent with previous studies by Mohlke and colleagues (Fig. 3 ) [14] . Plasma VWF from PERA/EiJ mice with Mvwf1 was cleared less quickly than the other two Mvwf1 strains. Plasma VWF from CAST/EiJ mice survived in plasma longer than that from C57BL/6J mice. VWF from C57BL/6J and VWF from A/J mice had similar half-lives, which corresponded to similar VWFpp/ VWF:Ag ratios for these two strains of mice (Table 4) . In contrast, all mice with Mvwf1 demonstrated a reduced VWF half-life and increased VWFpp/VWF:Ag ratio.
Interestingly, CAST/EiJ mice had a prolonged half-life compared with C57BL/6J mice and a reduced VWFpp/ VWF:Ag ratio, consistent with the increased steady-state VWF level in this strain. The reduced steady-state VWF level in mice with Mvwf1 results from increased VWF clearance from plasma and can be identified by an increased VWFpp/VWF:Ag ratio.
Discussion
From the data presented here, we can conclude that assay of murine VWF and its propeptide, VWFpp, has clear utility in determining the acceptability of murine plasma samples for coagulation studies. We identified vena cava collection as the most reliable method of murine phlebotomy that resulted in the least platelet and endothelial activation. A single retro-orbital blood collection was found to be a reliable non-terminal method of blood collection that resulted in only moderate, but consistent and reproducible, sample activation. Regulated release from both platelets and endothelial cells was identified as a significant source of released VWF during difficult phlebotomy in mice. The assay of VWFpp and VWF:Ag is also useful in identifying reduced VWF survival in mice with Mvwf1 and type 1C VWD phenotype. In humans, administration of DDAVP (1,8-deamino-Darginine vasopressin, also known as desmopressin) results in activation of endothelial cells and release of VWF and VWFpp, which is reflected by an increased VWFpp/ VWF:Ag ratio [5, 11] . Activation of platelets or endothelial cells during problematic murine phlebotomy also results in increased VWFpp/VWF:Ag, as was observed during repeated retro-orbital bleeds or cardiac puncture (Table 1 ). In fact, our calibrator suffers from a degree of activation as it was procured by cardiac puncture of numerous mice to produce a large pool to be used throughout this study. In order to use the ratio of VWFpp/VWF:Ag to identify a reduced VWF survival phenotype in mice, it is important to have a high-quality blood sample that has not been subject to activation of coagulation. In our study, vena cava bleed appeared to be the most reliable method with consistently low VWFpp/VWF:Ag. Some techniques, such as saphenous vein and tail vein bleeds, produced inconsistent degrees of platelet/endothelial activation with variable VWFpp/ VWF:Ag. However, we cannot exclude the possibility that these methods may become more consistent with practice. Other techniques, such as single retro-orbital and submandibular bleeds, demonstrated consistent results with only modestly increased VWFpp/VWF:Ag, with the advantage of being non-lethal. However, in our hands submandibular bleeding in Mvwf1 and VWF-/-mice often resulted in the unwanted loss of significant volumes of blood, suggesting this technique may not be practical for mice with a bleeding disorder. Although the vena cava bleed may be the optimal method, the disadvantage is the Our studies using mice expressing VWF in only platelets (plt-VWF) or endothelial cells (EC-VWF) demonstrated that VWF is released from both cell types during phlebotomy-associated activation (Fig. 1 ). There was a stark difference between vena cava and successive retroorbital bleeds in plt-VWF mice. VWF and VWFpp were undetectable in plasma after vena cava blood collection, indicating lack of platelet activation; both proteins remained safely sequestered in platelet a-granules. Multiple successive retro-orbital bleeds resulted in platelet activation and substantial release of VWFpp and VWF into plasma. The ratio of VWFpp/VWF:Ag (25.8) was markedly increased. One might expect that if all VWFpp and VWF were released from the platelets that VWFpp/VWF: Ag would be similar to that of platelet lysates (Table 3) as these mice had neither protein present in plasma at steady state to influence the ratio. However, this was not the case, as it appeared that more VWFpp was released than VWF. One explanation is that VWF remained tethered to the platelet surface after a-granule release while VWFpp was easily released into plasma. This phenomenon was previously observed when release of endothelial cell Weibel-Palade bodies was examined [24] . VWF remained tethered to the endothelial cell, presumably through binding to P-selectin or integrin a vb 3 [25] [26] [27] . In EC-VWF mice subjected to multiple retro-orbital bleeds, VWFpp was increased approximately 4-fold whereas VWF had a 1.7-fold increase and a VWFpp/ VWF:Ag ratio of 3, similar to the ratio observed in humans after DDAVP administration. EC-VWF mice after vena cava bleed had a ratio of approximately 1.0, consistent with that observed for C57BL/6J mice (Table 1) . We did not observe clotting of the samples with increased VWFpp/VWF:Ag, which would be a strong indicator of an unacceptable sample collection.
Analysis of mice with and without the Mvwf1 allele (Tables 2 and 3 , Fig. 2 ) demonstrated a phenotype in Mvwf1-positive mice that is similar to that observed in human type 1C VWD patients. These mice had reduced plasma VWF:Ag, normal VWFpp (with the exception of Tie2-B4galnt2), normal multimers and reduced VWF half-life in plasma. The reduced VWF survival was predicted by an increased VWFpp/VWF:Ag ratio in these mice. The VWF:Ag content in platelets in these mice was found to be comparable to mice without the Mvwf1 allele. In humans with type 1 VWD, this phenotype would correspond to the historic 'platelet-normal' type 1 VWD [28] . The 'platelet normal' type 1 VWD was designated prior to studies examining VWF clearance. This designation likely corresponds to the current 'type 1C' VWD phenotype. Based upon our studies, RIIIS/J and PERA/EiJ mice have a 'classic' type 1C VWD phenotype with normal VWF synthesis/secretion and reduced plasma VWF survival. Tie2-B4galnt2 mice demonstrated both reduced secretion (reduced plasma VWFpp) and reduced plasma VWF survival.
In mice without Mvwf1, C57BL/6J and A/J mice appeared to have very similar VWF laboratory parameters, consistent with a 'normal' murine VWF phenotype and no evidence of reduced VWF secretion or survival. CAST/EiJ mice had increased VWF:Ag levels compared Mice were bled retro-orbitally under anesthesia at designated time-points with n = 4, at minimum, used for each group. Each sample was assayed for murine VWF:Ag by ELISA. Data were normalized to % of initial VWF injected. VWF from mice with Mvwf1 was cleared more quickly than that from mice without Mvwf1. with C57BL/6J or A/J mice, as has been previously reported [18] . This previous study implicated enhanced synthesis as the mechanism underlying the increased VWF level, with expression studies demonstrating a 1.3-fold increase in VWF expression. VWFpp has been used as a marker of VWF synthesis and secretion in humans [8, 10, [29] [30] [31] . In our study, murine VWFpp levels were 0.78 and 0.58 U mL À1 for CAST/EiJ and C57BL/6J, respectively, corresponding to a 1.34-fold increase in VWF synthesis and secretion, which is consistent with the previously reported expression studies. We also observed an increased VWF half-life for CAST/EiJ mice (13.7 h vs. 4.2 h for C57BL/6J), indicating that increased VWF survival, in addition to enhanced VWF synthesis, may explain the increased VWF level in the CAST/EiJ mouse. The increased VWF half-life was consistent with the reduced VWFpp/VWF:Ag of 0.2 in CAST/EiJ mice. The assay of plasma VWFpp and VWF:Ag has utility in identifying a reduced VWF survival phenotype in mice as well as in humans.
In sum, we have demonstrated that the assay of VWFpp and VWF:Ag has clear utility in determining the acceptability of murine plasma samples as well as identifying a reduced VWF survival phenotype. Vena cava collection is a reliable method of murine phlebotomy with little sample activation, which is important when studying coagulation in murine models.
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